Other tumors with more marked levels of PTEN SCNA gain are ovarian (OV) 81 (19.66%), esophageal carcinoma (ESCA) 23 (12.71%), lung adenocarcinoma (LUAD) 73 (14.34%), stomach adenocarcinoma (STAD) 48 (11.59%) and hepatocellular carcinoma of the liver (LIHC) 35 (9.70%). This evidence concerns the gene PTEN and gastric adenocarcinoma.